[go: up one dir, main page]

JPS6485092A - Production of protein - Google Patents

Production of protein

Info

Publication number
JPS6485092A
JPS6485092A JP62240513A JP24051387A JPS6485092A JP S6485092 A JPS6485092 A JP S6485092A JP 62240513 A JP62240513 A JP 62240513A JP 24051387 A JP24051387 A JP 24051387A JP S6485092 A JPS6485092 A JP S6485092A
Authority
JP
Japan
Prior art keywords
protein
useful protein
vaccinia virus
dna coding
hiv tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62240513A
Other languages
Japanese (ja)
Inventor
Asato Kojima
Takeshi Kurata
Atsushi Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeon Corp
National Institutes of Health NIH
Original Assignee
Nippon Zeon Co Ltd
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zeon Co Ltd, National Institutes of Health NIH filed Critical Nippon Zeon Co Ltd
Priority to JP62240513A priority Critical patent/JPS6485092A/en
Publication of JPS6485092A publication Critical patent/JPS6485092A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE:To produce useful protein in high efficiency, by proliferating a recombinant vaccinia virus including DNA coding a useful protein in the presence of human AIDS virus HIV tat-protein. CONSTITUTION:A recombinant vaccinia virus which has a DNA coding a useful protein inserted into the genome region not essential for proliferation of vaccinia virus is proliferated in the presence of a human AIDS virus HIV tat-protein in a usual manner, e.g., using PK-13 as host cells, at about 36-39 deg.C for 1-7 days. After completion of culture, the useful protein is collected from the culture supernatant and the cultured cells.
JP62240513A 1987-09-25 1987-09-25 Production of protein Pending JPS6485092A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62240513A JPS6485092A (en) 1987-09-25 1987-09-25 Production of protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62240513A JPS6485092A (en) 1987-09-25 1987-09-25 Production of protein

Publications (1)

Publication Number Publication Date
JPS6485092A true JPS6485092A (en) 1989-03-30

Family

ID=17060637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62240513A Pending JPS6485092A (en) 1987-09-25 1987-09-25 Production of protein

Country Status (1)

Country Link
JP (1) JPS6485092A (en)

Similar Documents

Publication Publication Date Title
NO874750L (en) Certain DNA sequences derived from a papilloma virus genome, their use in in vitro diagnostics and production of antigenic preparations.
ES2127458T3 (en) PROTEIN PRODUCTION USING HOMOLOGICAL RECOMBINATION.
JPS6479124A (en) Factor viii analogue, manufacture and medicine
YU45871B (en) POLYPEPTIDE WITH HUMAN IMMUNOINTERFERON (IFN-GAMMA) PROPERTIES
EP0752874A4 (en) Enhanced virus-mediated dna transfer
ES8708251A1 (en) Process for the preparation of Insulin Precursors and process for the preparation of human insulin.
ATE77104T1 (en) QUANTITY AND METHOD FOR MAKING HIGH YIELD RECOMBINATION PRODUCTS.
ATE120234T1 (en) HIV-3 RETROVIRUS AND ITS USE.
AU554080B2 (en) Production of viral antisens
GB8914968D0 (en) Production of virus and purification of viral envelope proteins for vaccine use
ES8608581A1 (en) Synthetic genes for bovine parainfluenza virus
HUP0101081A2 (en) Medium and method for viral propagation and growth
KR900702045A (en) How to prepare natural HIV GP 160
JPS6485092A (en) Production of protein
AR005823A1 (en) PROCESS TO PRODUCE A CELL FREE ZOSTER VARICELLA VIRUS
EP0112012A3 (en) Recombinant DNA molecules
CN104178494A (en) Preparation process and application of human interleukin 2 (IL-2)
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements
ATE266094T1 (en) PRODUCTION OF THE PROTEIN INGAP WITH HIGH EXPRESSION RATE
MY104975A (en) Protease, reverse transcriptase and endonuclease of retrovirus, and method for producing these enzymes.
EP1309342A4 (en) Production of chimeric human papillomavirus
FR2261779A1 (en) Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium
JPS6485072A (en) Recombinant vaccinia virus
JPS6485094A (en) Novel physiologically active polypeptide
FI98466B (en) Isolated DNA and RNA molecules of the western subtype of FSME virus, vectors and cell cultures containing them, and a method for producing the peptides encoded by them